September 28, 2022
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

Sientra stock falls after company warned by FDA over study

IN THIS ARTICLE

Updated: 5:00 p.m. March 20 Shares for Goleta-based breast implant developer Sientra fell 4.5 percent March 19 after the company received a warning letter from the U.S. Food and Drug Administration related to long-term studies of its products. The FDA said in the letter that Sientra had failed to comply with post-approval study requirements, including…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.